This study focuses on individuals with early Breast Cancer that has a specific type known as Luminal A. This means the cancer cells are Hormone Receptor Positive, meaning they rely on hormones like estrogen and progesterone to grow, and they are HER2-negative, which means they lack a specific protein that can promote cancer growth. The study is designed for patients who are postmenopausal and have a low risk of the cancer returning. The goal of the study is to determine if it is safe to skip Endocrine Therapy, which is a type of treatment that uses drugs to block hormones, in patients who have already had surgery and radiation.

In this trial, participants will be monitored to see how long they remain free from the cancer returning. The medications typically used in such treatments include Exemestane, Anastrozole, Letrozole, and Tamoxifen. These drugs are taken orally to prevent the cancer from growing back by interfering with the body’s hormone levels. During the course of the study, researchers will observe the participants over several years to track their health and monitor for any signs of the disease returning in the breast or in other parts of the body.